Selçuk Mahmut
Department of Psychiatry, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey.
Psychiatry Clin Psychopharmacol. 2023 Jun 1;33(2):143-146. doi: 10.5152/pcp.2023.23651. eCollection 2023 Jun.
Atypical antipsychotic clozapine has a special therapeutic impact on tardive dyskinesia and treatment-resistant schizophrenia. Clozapine also has important adverse effects such as epileptic seizures. For this reason, most clinicians avoid using clozapine in patients with schizophrenia and epilepsy. Therefore, treating patients with schizophrenia, tardive dyskinesia, and epilepsy is challenging. Here, we describe the case of a 32-year-old woman who was already suffering from epilepsy, schizophrenia, and tardive dyskinesia. She experienced clozapine-related seizures. But at the same time, clozapine dose adjustments successfully improved her psychosis and tardive dyskinesia and also stabilized her epilepsy. This case study indicates that epilepsy does not preclude the use of this important agent whenever it is clinically appropriate.
非典型抗精神病药物氯氮平对迟发性运动障碍和难治性精神分裂症具有特殊的治疗作用。氯氮平也有重要的不良反应,如癫痫发作。因此,大多数临床医生避免在患有精神分裂症和癫痫的患者中使用氯氮平。所以,治疗患有精神分裂症、迟发性运动障碍和癫痫的患者具有挑战性。在此,我们描述了一名32岁女性的病例,她已患有癫痫、精神分裂症和迟发性运动障碍。她经历了与氯氮平相关的癫痫发作。但与此同时,氯氮平剂量调整成功改善了她的精神病症状和迟发性运动障碍,也稳定了她的癫痫病情。该病例研究表明,只要临床适用,癫痫并不排除使用这种重要药物。